Patients with hematological malignancies are at an increased risk of SARS-CoV-2 disease (COVID-19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID-19.

The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population

Bonifacio, Massimiliano
;
Scaffidi, Luigi;Cordioli, Maddalena;Tanasi, Ilaria;Tacconelli, Evelina;Pizzolo, Giovanni;Krampera, Mauro
2021

Abstract

Patients with hematological malignancies are at an increased risk of SARS-CoV-2 disease (COVID-19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID-19.
COVID-19; TKIs; chronic myeloid leukemia; prevalence; serological tests
File in questo prodotto:
File Dimensione Formato  
cam4.4179-2.pdf

accesso aperto

Tipologia: Versione dell'editore
Licenza: Creative commons
Dimensione 283.02 kB
Formato Adobe PDF
283.02 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/1048080
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact